Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:54:59 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q5.10.37·0.420.50.40+0.046513.29,966.03,5424,9890.3673  0.40  0.35851.29  0.34519:59:48Feb 0315 min RT 2¢

Recent Trades - Last 10 of 4989
Time ETExPriceChangeVolume
19:59:48Q0.40980.05631
19:59:12Q0.40850.055500
19:56:00Q0.40990.056470
19:51:56Q0.410.0565576
19:50:41Q0.40870.05521,000
19:49:46Q0.410.05651
19:48:40Q0.410.0565500
19:44:12Q0.410.056551
19:44:12Q0.410.0565100
19:44:12Q0.410.0565997

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 16:05U:SGMONews ReleaseSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
2026-02-03 09:11U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
2025-12-18 08:05U:SGMONews ReleaseSangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2025-12-02 08:05U:SGMONews ReleaseSangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
2025-11-21 08:05U:SGMONews ReleaseSangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
2025-11-06 08:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
2025-10-30 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2025 Earnings Call
2025-09-04 08:05U:SGMONews ReleaseSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
2025-08-07 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
2025-07-31 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2025 Earnings Call
2025-06-24 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
2025-05-12 18:26U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-12 18:23U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
2025-05-12 16:00U:SGMONews ReleaseSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2025-04-03 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
2025-03-17 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-06 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference